Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H14O4.2Na |
Molecular Weight | 232.1846 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].[O-]C(=O)CCCCCCCC([O-])=O
InChI
InChIKey=QFYNUCAKHMSPCY-UHFFFAOYSA-L
InChI=1S/C9H16O4.2Na/c10-8(11)6-4-2-1-3-5-7-9(12)13;;/h1-7H2,(H,10,11)(H,12,13);;/q;2*+1/p-2
Molecular Formula | Na |
Molecular Weight | 22.98976928 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C9H14O4 |
Molecular Weight | 186.2051 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=2114832
https://www.ncbi.nlm.nih.gov/pubmed/18803456
Azelaic acid, a naturally occurring saturated dicarboxylic acid found in wheat, rye, and barley, possesses antimicrobial activity, affects keratin production, and reduces inflammation. One of the brand name for azelaic acid is FINACEA,Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema, which was present in patients with papules, and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Rosacea is a common skin condition thought to be primarily an inflammatory disorder. Neutrophils, in particular, have been implicated in the inflammation associated with rosacea and mediate many of their effects through the release of reactive oxygen species. Many effective agents for rosacea, including topical azelaic acid have anti-inflammatory properties. Azelaic acid per se has multiple modes of action in rosacea, but an anti-inflammatory effect achieved by reducing reactive oxygen species appears to be the main pharmacological action. A possible mechanism of action for azelaic acid in the human epidermis includes its possibility to inhibit tyrosinase and of membrane-associated thioredoxin reductase enzymes, this enzyme is shown to regulate tyrosinase through a feedback mechanism involving electron transfer to intracellular thioredoxin, followed by a specific interaction between reduced thioredoxin and tyrosinase.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2505463
Curator's Comment: Azelaic acid is capable of crossing the blood-brain barrier: its concentration in the cerebrospinal fluid is normally in the range of 2-5% of the values in the serum.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P14679 Gene ID: 7299.0 Gene Symbol: TYR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
2.73 mM [Ki] | ||
Target ID: CHEMBL2096978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2114832 |
125.0 mM [Ki] | ||
Target ID: GO:1903409 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20967185 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | FINACEA Approved UseFINACEA® (azelaic acid) Gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to
moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of
rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules
has not been evaluated. Launch Date2002 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112 ng/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
136 ng/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
613 ng × h/mL |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
686 ng × h/mL |
1 g 2 times / day steady-state, topical dose: 1 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h |
1 g single, topical dose: 1 g route of administration: Topical experiment type: SINGLE co-administered: |
AZELAIC ACID plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Sensitive and accurate quantitation of monoepoxy fatty acids in thermoxidized oils by gas-liquid chromatography. | 2002 Dec 20 |
|
A status report on the medical management of rosacea: focus on topical therapies. | 2002 Nov |
|
Unknown peaks in GC-MS analyses of Guthrie cards blood samples might be the result of sample contamination by the black markings of the card. | 2002 Oct |
|
Guidelines for the management of acne vulgaris in adolescents. | 2003 |
|
Topical treatment in acne: current status and future aspects. | 2003 |
|
Urotropin azelate: a rather unwilling co-crystal. | 2003 Feb |
|
Management of acne. | 2003 Jan |
|
Atmospheric pressure mass spectrometry: a new analytical chemical characterization method for dissolved organic matter in rainwater. | 2003 Jan 1 |
|
Gas chromatography-mass spectrometry profile of urinary organic acids of Wistar rats orally treated with ozonized unsaturated triglycerides and ozonized sunflower oil. | 2003 Jan 15 |
|
Immunochemical detection of a novel lysine adduct using an antibody to linoleic acid hydroperoxide-modified protein. | 2003 Jun |
|
Acne and its management beyond the age of 35 years. | 2004 |
|
Photoelectron resonance capture ionization mass spectrometry: a soft ionization source for mass spectrometry of particle-phase organic compounds. | 2004 |
|
Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. | 2004 |
|
Azelaic acid : a viewpoint by Aditya K. Gupta. | 2004 |
|
Evaluation of the antibacterial efficacy of diesters of azelaic acid. | 2004 Apr |
|
Rosacea. An overview of diagnosis and management. | 2004 Dec |
|
New rosacea drug gets the red out. | 2004 Jan |
|
The role of topical metronidazole in the treatment of rosacea. | 2004 Jan |
|
Azelaic acid, a new treatment for rosacea. | 2004 Jun |
|
Topical agents used in the management of hyperpigmentation. | 2004 Jun-Jul |
|
Conformationally constrained dipeptide surrogates with aromatic side-chains: synthesis of 4-aryl indolizidin-9-one amino acids by conjugate addition to a common alpha,omega-diaminoazelate enone intermediate. | 2004 Mar 5 |
|
A case of idiopathic eruptive macular pigmentation. | 2004 May |
|
Diagnosis and treatment of acne. | 2004 May 1 |
|
Differential conductance switching of planar tunnel junctions mediated by oxidation/reduction of functionally protected ferrocene. | 2004 May 26 |
|
Ethosomes and liposomes as topical vehicles for azelaic acid: a preformulation study. | 2004 May-Jun |
|
Rosacea: where are we now? | 2004 May-Jun |
|
Hyperpigmentation: an overview of the common afflictions. | 2004 Oct |
|
Noxious sensory perceptions in patients with mild to moderate rosacea treated with azelaic acid 15% gel. | 2004 Oct |
|
Comparison of 15% azelaic acid gel and 0.75% metronidazole gel for the topical treatment of papulopustular rosacea. | 2004 Oct |
|
Aerosol products, mechanisms, and kinetics of heterogeneous reactions of ozone with oleic acid in pure and mixed particles. | 2005 |
|
Rosacea: an update. | 2005 |
|
Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin. | 2005 Apr 11 |
|
Considerations for treating acne in ethnic skin. | 2005 Aug |
|
Chemical modification of proteins during peroxidation of phospholipids. | 2005 Jul |
|
Acne vulgaris. | 2005 Jun |
|
Lipid-derived modifications of plasma proteins in experimental and human diabetes. | 2005 Jun |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Ion chromatographic analysis of amines, alkanolamines, and associated anions in concrete. | 2005 Mar |
|
The rigor of trials evaluating Rosacea treatments. | 2005 Mar |
|
Evidence-based dermatology. | 2005 Mar |
|
Present and future rosacea therapy. | 2005 Mar |
|
Alpha-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes is mediated via thioredoxin-1-sensitive oxidative modification of thiols on Ras. | 2005 Mar 8 |
|
Face up to rosacea. | 2005 Sep |
|
Red facial rash with "granitos". | 2005 Sep |
|
[Rosacea. Clinical features, pathogenesis and therapy]. | 2005 Sep |
|
Case studies. | 2006 Feb |
|
A clinical overview of azelaic acid. | 2006 Feb |
|
The evolution of azelaic acid. | 2006 Feb |
|
Topical therapies for rosacea. | 2006 Jan |
|
Treatment of melasma. | 2006 May |
Patents
Sample Use Guides
Apply and gently massage into the affected areas on the face twice daily (morning and evening). Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7640879
Using a clonogenic assay in vitro, it has been shown that exposure to azelaic acid (1-100 mM) for 24 hours has a dose-dependent effect on the survival of the colony-forming ability of murine (B16) and human (HMB2, and SK23) melanoma cells as compared with a non-melanotic non-tumoral Chinese hamster cell line (CHO). Both human cell lines were more sensitive to the diacid than the murine cells, and the HMB2 cells were more sensitive than the SK23 cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 18:20:10 GMT 2025
by
admin
on
Wed Apr 02 18:20:10 GMT 2025
|
Record UNII |
0P4H8NH3UJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
27825-99-6
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C010038
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
DTXSID40889659
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
17265-13-3
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
0P4H8NH3UJ
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
159815
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
2117384
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY | |||
|
241-298-4
Created by
admin on Wed Apr 02 18:20:10 GMT 2025 , Edited by admin on Wed Apr 02 18:20:10 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|